The Nifty opened at 14712.45 with a gap down of 102 points. The index recorded its intraday high at 14752.35 then fell down. Prices have seen a decline of almost 170 points and then started moving sideways. However in the last hour of trading, the index has seen another round of selling and finally closed at 14549.40 with a loss of 265.35. All the sectoral indices have seen a decline except Pharma. The Metal, Banks and Auto have led the bears and closed lower by more than 2%. A relied rally ended as the index closed below 14600. It was a trend day on the downside. Prices have resumed its short term down trend after three days of a relief rally. The index is now trading near its strong support at 14500. If prices breaks and closed below 14500 then the next support may emerge around 14200. As of now the short term trend is on the downside.

The trade was to buy above 14900 or sell short below 14700. Prices opened with a gap down but above 14700 and broke that level intraday. So our short trade was executed. We had suggested a stop of 120 points and a target of 280 points. We are advising traders to stayshort with a stop at breakeven and target near 14200.

Trade AnyTime AnyWhere With Elite Empower Mobile App



Bank Nifty opened at 33894.70 with a gap down of almost 329 points. The index seen a minor rally and recorded its intraday high at 33970.65 and then drifted downwards. Prices have seen an intraday decline of almost 600 points and then spent the rest of the day trading choppy and narrow. The index recorded its intraday low at 33376.75 and finally closed lower by more than 800 points. Private and PSU Banks have contributed in the decline and closed lower by almost 3%. Within the index in terms of points ICICI Bank contributed highest on the downside followed by Axis Bank. We have suggested a trade in the direction of breakout. The trade was to buy above 34400 or sell below 33200. We are recommending the same trade for today as the trade did not execute yesterday.


AUROPHARMA 855.85 BUY The stock has given a breakout from a narrow trading range. The stock can be bought at CMP with a stop at 840 and for the target 880.
ADANIENT 1025.45 SELL The stock has given a breakdown from a narrow trading range. The stock can be sold at CMP with a stop at 1034 and for the target 1000.



STOCK OPTION Strike Price Buy/Sell CMP Initiation Stop Loss Target Remarks
HINDALCO 315 PE BUY 2.2 CMP 0.8 5 OI increase


Long Buildup Short Buildup
Stocks Price Price% OI % OI Stocks Price Price% OI % OI
BERGEPAINT.21.03 Mar 746 0.05 17.84 1431100 BHARATFORG.21.03 Mar 580.95 -2.39 31.74 3997500
ASIANPAINT.21.03 Mar 2445 1.28 10.62 1839900 NTPC.21.03 Mar 106.3 -2.39 29.59 30432300
CIPLA.21.03 Mar 789.75 1.5 4.69 6419400 DABUR.21.03 Mar 530.55 -0.7 28.31 5416250
MARICO.21.03 Mar 401.25 0.25 4.68 3492000 INDUSINDBK.21.03 Mar 962.15 -2.91 28.11 11379600
AUROPHARMA.21.03 Mar 858.65 1.32 2.84 3677700 GODREJCP.21.03 Mar 683.55 -1.04 24.8 3654000
                                                                        Short Covering Long Unwinding
Stocks Price Price% OI% OI Stocks Price Price % OI % OI
MGL.21.03 Mar 1162.65 0.29 -17.93 343200 MINDTREE.21.03 Mar 1982.1 -1.46 -34.04 525600
AARTIIND.21.03 Mar 1325.55 2.48 -3.99 163625 M&MFIN.21.03 Mar 201.25 -4.58 -31.25 4216000
POWERGRID.21.03 Mar 220.4 0.25 -3.18 9148000 CHOLAFIN.21.03 Mar 548.5 -2.21 -30.26 1192500
RAMCOCEM.21.03 Mar 961.8 -2.55 -27.93 434350
IDFCFIRSTB.21.03 Mar 59 -3.91 -26.22 34808000

Get All Your Mutual Fund Portfolio Returns on Your Mobile by Elite Kuber App


Top Delivery Percentage

Stocks Price %Chg Total Qty Delivery Del % % Change
Sectors Price Change % Quantity
Piind 2305.05 0.15 218205 338228 77.9 Nifty Pharma 11916.3 0.08 81171
Power Grid Corporation o 221.05 0.94 13724418 15472550 71.53 Nifty it 25802.95 -1.16 81171
Alembic Pharmaceuticals 936.8 0.42 349869 558805 71.21 Nifty Fmcg 33987.1 -1.41 81171
Lalpathlab 2477.2 -3.12 147901 220461 68.74 Nifty Energy 18676.75 -1.73 81171
Icici Lombard General In 1402.85 -2.45 430059 282311 66.79 Nifty 50 14549.4 -1.79 81171
Vedanta Limited 223.4 -0.16 20887559 11502620 63.36 Nifty Media 1592.35 -2.48 81171
Hindustan Unilever Ltd 2318.6 -0.8 1762743 1219523 61.89 Nifty Auto 9925.25 -2.58 81171
Hdfc Ltd. 2465.75 -1.76 3165420 2450626 61.56 Nifty Bank 33293.25 -2.61 81171
Infosys Limited 1353.75 -1.3 6134303 4362930 60.89 Nifty Realty 331.45 -2.94 81171
Indraprastha Gas Limited 515 -0.84 2439619 1965428 59.59 Nifty Metal 3717.55 -3.24 81171

Upcoming Economic Data

   Domestic                                                                                                                                                  International
INR:  FX Reserves, USD on 26th  March, 2021

INR:  Bank Loan Growth  on 26th  March, 2021

•USD : Initial Jobless Claims on 25nd March, 2021

•USD:  GDP (QoQ) (Q4) on 25th March, 2021

Get Stock Market Recommendation By Our Research Analysts


News Updates

  • The Adani Road Transport Ltd (ARTL) on Wednesday said it has won a Rs 1039.90 crore highway project from NHAI in Telangana. The bid cost of the project is Rs 1,039.90 crore, it added. The construction period of the project is two years, while the operation period is 15 years, it noted. ARTL is a wholly-owned subsidiary of Adani Enterprises Limited (AEL), part of Adani Group.

  • Amid a spike in COVID-19 infections in some parts of the country, the Centre on Wednesday asked states and union territories to consider imposing local restrictions in public observance of the upcoming festivals and limit or do away with mass gatherings for effective control of the pandemic.

  • Escorts Limited’s Escorts Agri Machinery (EAM) division announced hike in prices of all its tractors with effect from 1 April, 2021. The price hike, the company said in a regulatory filing, is due to a steady rise in commodity prices.

  • Cadila Healthcare on Wednesday said the company and its subsidiary Zydus Pharmaceuticals (USA) Inc have reached a settlement with US-based firm Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb, over patents for the anti-cancer drug Revlimid.

  • Privatisation of two public sector banks can impact their ratings as the government support to the two entities will disappear, India Ratings and Research said on Wednesday.

Source: Economic Times,  Moneycontrol  ,Business Today, Livemint, Business Standard, Bloomberg Quint

Open Your Demat Account to Invest in Upcoming IPO’sDemat-and-Trading-Account-Promotion-Banner

Board Meetings

Company Name Purpose Ex-Date Company Name Purpose Ex-Date
AHMDSTE General 25-Mar-21 SRTRANSFIN Interim Dividend 25-Mar-21
CGPOWER General;Preferential Issue of shares 25-Mar-21 TERRASCOPE General 25-Mar-21
CHROMATIC Quarterly Results 25-Mar-21 UNIVSTAR General 25-Mar-21
EDELWEISS Interim Dividend 25-Mar-21 ABMKNO General 26-Mar-21
FERVENTSYN General 25-Mar-21 CEINSYSTECH General 26-Mar-21
GOVINDRU Reduction of Capital 25-Mar-21 DSSL Issue Of Warrants;General 26-Mar-21
GVFILM General 25-Mar-21 IDBI General 26-Mar-21
HKG General 25-Mar-21 INDNIPPON Interim Dividend 26-Mar-21
JAYIND General 25-Mar-21 INDSUCR Issue Of Warrants;General 26-Mar-21
JYOTIRES General 25-Mar-21 KREONFIN General 26-Mar-21
SBILIFE Interim Dividend 25-Mar-21 LUMAXIND General 26-Mar-21

Corporate Action

Company Name Ex-Date Purpose Company Name Ex-Date Purpose
BPCL 25-Mar-21 Interim Dividend – Rs. – 5.00 AARTIDRUGS 30-Mar-21 Buy Back of Shares
HUDCO 25-Mar-21 Interim Dividend – Rs. – 0.7500 ACC 30-Mar-21 Final Dividend – Rs. – 14.00
RELTD 25-Mar-21 E.G.M. COLPAL 30-Mar-21 Interim Dividend – Rs. – 20.00
GFLLIMITED 26-Mar-21 Spin Off CRISIL 30-Mar-21 Final Dividend – Rs. – 14.00
INDIGRID 26-Mar-21 Right Issue of Equity Shares EASTWEST 30-Mar-21 Stock  Split From Rs.10/- to Rs.2/-
SPACEAGE 26-Mar-21 E.G.M. EASTWEST 30-Mar-21 Bonus issue 1:4

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Israil Khan, Elite Wealth Limited,
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit Disclosures Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting , or e-mailing with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person. Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, advisory board member or employee of any company in the analyst’s area of coverage. Country Specific Disclosures India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website:
EWL Advisory discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL Advisory or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL Advisory or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL Advisory or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
2. Compensation
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL Advisory or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL Advisory or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL Advisory or its associates have not received any compensation for products or services other than investment banking
or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL Advisory or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL Advisory
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL Advisory or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL Advisory has never been engaged in market making activity for the subject company;
(6) EWL Advisory shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.